Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

PHIO

Phio Pharmaceuticals Corp

Last Close
May 15 • 03:44PM ET
0.7840
Dollar change
+0.0502
Percentage change
6.84 		%
Held by: VXF Scroll to Statements
Index- P/E- EPS (ttm)-3.59 Insider Own1.54% Shs Outstand4.59M Perf Week-2.00%
Market Cap3.60M Forward P/E0.21 EPS next Y3.78 Insider Trans3.67% Shs Float4.52M Perf Month19.84%
Income-9.38M PEG- EPS next Q-0.51 Inst Own10.61% Short Float4.09% Perf Quarter15.98%
Sales0.00M P/S- EPS this Y65.00% Inst Trans-17.61% Short Ratio0.43 Perf Half Y-23.30%
Book/sh1.22 P/B0.64 EPS next Y307.69% ROA-113.26% Short Interest0.18M Perf Year-76.74%
Cash/sh1.41 P/C0.56 EPS next 5Y- ROE-145.23% 52W Range0.50 - 6.85 Perf YTD3.16%
Dividend Est.- P/FCF- EPS past 5Y62.38% ROI-167.34% 52W High-88.55% Beta1.41
Dividend TTM- Quick Ratio5.48 Sales past 5Y-36.96% Gross Margin- 52W Low56.80% ATR (14)0.08
Dividend Ex-Date- Current Ratio5.48 EPS Y/Y TTM67.11% Oper. Margin0.00% RSI (14)53.57 Volatility10.33% 12.60%
Employees9 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q85.09% Payout- Rel Volume0.25 Prev Close0.73
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 09 AMC Avg Volume427.42K Price0.78
SMA206.97% SMA501.00% SMA200-32.84% Trades Volume102,189 Change6.84%
Date Action Analyst Rating Change Price Target Change
Aug-05-20Initiated H.C. Wainwright Buy $4
Today 01:00PM
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
(GlobeNewswire) +6.84%
May-09-24 11:53PM
PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024
(InvestorPlace)
05:25PM
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
(GlobeNewswire)
Apr-30-24 07:30AM
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
(GlobeNewswire)
Apr-22-24 01:10PM
Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
(GlobeNewswire) +29.69%
07:30AM Loading…
Apr-16-24 07:30AM
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
(GlobeNewswire)
Apr-11-24 07:30AM
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
(GlobeNewswire)
Apr-03-24 07:30AM
National Spotlight Features Phio's Innovative RNAi Technology Platform
(GlobeNewswire)
Apr-02-24 07:30AM
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
(GlobeNewswire)
Mar-21-24 07:30AM
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
(GlobeNewswire) -21.50%
Mar-13-24 02:00PM
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
(GlobeNewswire)
Mar-06-24 10:30AM
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
(GlobeNewswire) +6.63%
Jan-31-24 08:00AM
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
(GlobeNewswire)
Dec-07-23 08:00AM
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
(GlobeNewswire) -42.14%
Nov-09-23 04:30PM
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire) -10.53%
07:30AM Loading…
07:30AM
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
(GlobeNewswire)
Nov-03-23 12:00PM
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
(GlobeNewswire) +6.57%
Oct-12-23 11:00AM
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(GlobeNewswire) -32.31%
Oct-11-23 07:30AM
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894
(GlobeNewswire) +87.05%
Sep-06-23 07:30AM
Phio CEO to Speak at Wainwright Conference in New York in September
(GlobeNewswire)
Aug-21-23 07:30AM
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
(GlobeNewswire)
Aug-10-23 04:30PM
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Jun-02-23 01:30PM
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
(PR Newswire)
May-31-23 08:00AM
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
(PR Newswire) -13.15%
May-24-23 07:30AM
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
(PR Newswire)
May-18-23 12:00PM
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
(PR Newswire) +34.31%
May-16-23 07:30AM
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
(PR Newswire) +21.36%
May-11-23 05:00PM
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
(PR Newswire)
Apr-20-23 02:20PM
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(PR Newswire)
Apr-18-23 12:10PM
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(PR Newswire) -19.24%
07:30AM Loading…
07:30AM
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
(PR Newswire)
Apr-17-23 07:30AM
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
(PR Newswire) +18.48%
Mar-22-23 05:05PM
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update
(PR Newswire)
Feb-22-23 07:30AM
Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer
(PR Newswire)
Feb-13-23 07:30AM
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
(PR Newswire)
Feb-10-23 07:30AM
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
(PR Newswire) -11.68%
Jan-25-23 08:30AM
Phio Pharmaceuticals Announces Reverse Stock Split
(PR Newswire) -6.45%
Jan-06-23 04:30PM
Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco
(PR Newswire) +40.26%
01:30PM
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors
(PR Newswire)
Dec-21-22 04:15PM
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
(PR Newswire)
Nov-10-22 06:25PM
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
(Zacks) -7.13%
05:05PM
Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update
(PR Newswire)
09:00AM
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th
(PR Newswire)
Oct-25-22 12:00PM
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
(Zacks)
Oct-12-22 09:38AM
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
(Zacks) +9.19%
Oct-07-22 05:42PM
Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia
(Zacks)
Oct-06-22 07:30AM
Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(PR Newswire)
Sep-29-22 08:30AM
Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman
(PR Newswire) -5.20%
Sep-27-22 03:51PM
Encompass Health (EHC) Plans Hospital to Aid Florida Footprint
(Zacks)
Sep-26-22 12:09PM
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug
(Zacks)
Sep-22-22 07:30AM
Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference
(PR Newswire)
Sep-12-22 07:30AM
Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(PR Newswire)
Aug-11-22 05:00PM
Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
(PR Newswire)
Jul-11-22 06:53AM
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Is About To Turn The Corner
(Simply Wall St.)
Jun-06-22 02:15PM
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
(PR Newswire)
May-16-22 12:22PM
Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells
(Benzinga)
08:00AM
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
(PR Newswire)
May-12-22 04:50PM
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
(PR Newswire)
May-05-22 08:33AM
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
(PR Newswire)
May-03-22 07:30AM
Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022
(PR Newswire)
May-02-22 04:30PM
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022
(PR Newswire)
07:30AM
Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors
(PR Newswire)
Apr-26-22 10:15AM
Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma
(PR Newswire) -8.77%
Apr-18-22 09:30AM
Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer
(PR Newswire)
Apr-11-22 03:39PM
We're Keeping An Eye On Phio Pharmaceuticals' (NASDAQ:PHIO) Cash Burn Rate
(Simply Wall St.) -25.53%
10:41AM
Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism
(GlobeNewswire)
Apr-08-22 01:00PM
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
(PR Newswire) +159.18%
Mar-22-22 05:00PM
Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update
(PR Newswire)
Mar-08-22 04:30PM
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022
(PR Newswire) +5.71%
Feb-22-22 09:30AM
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2
(PR Newswire)
Jan-11-22 12:30PM
3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today
(InvestorPlace) +8.41%
07:30AM
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
(PR Newswire)
Jan-03-22 07:30AM
Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference
(PR Newswire) +9.00%
Dec-06-21 09:28AM
Analysts Expect Breakeven For Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Before Long
(Simply Wall St.) +5.08%
Nov-12-21 07:00AM
Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting
(PR Newswire)
Nov-10-21 04:40PM
Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
(PR Newswire)
Oct-18-21 07:05AM
Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting
(PR Newswire)
Oct-07-21 09:00AM
Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(PR Newswire)
Sep-30-21 08:05AM
Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021
(PR Newswire)
Sep-16-21 12:12PM
38 Stocks Moving In Thursday's Mid-Day Session
(Benzinga) +10.66%
08:08AM
Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation
(Benzinga)
07:40AM
20 Stocks Moving in Thursday's Pre-Market Session
(Benzinga)
07:05AM
Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4
(PR Newswire)
Sep-03-21 07:05AM
Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th
(PR Newswire)
Aug-31-21 08:05AM
Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021
(PR Newswire) +8.33%
Aug-12-21 05:00PM
Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
(PR Newswire)
Jul-07-21 04:30PM
Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th
(PR Newswire)
Jun-22-21 11:04AM
Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th
(PR Newswire)
Jun-14-21 04:09PM
Is Phio Pharmaceuticals Corp. (PHIO) A Good Stock To Buy?
(Insider Monkey) +9.05%
08:00AM
Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June
(PR Newswire)
Jun-04-21 08:00AM
Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches
(PR Newswire)
May-13-21 05:00PM
Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
(PR Newswire) -8.78%
May-11-21 01:10PM
Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies
(Benzinga) -14.12%
08:00AM
Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells
(PR Newswire)
Apr-29-21 07:30AM
Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings
(PR Newswire)
Apr-12-21 07:33AM
Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies
(Benzinga) -10.95%
Apr-10-21 08:30AM
Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL RNAi Targeting PD-1
(PR Newswire)
Mar-25-21 05:15PM
Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update
(PR Newswire)
Mar-11-21 07:30AM
Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting
(PR Newswire) +10.92%
Mar-01-21 08:00AM
Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies
(PR Newswire) +7.69%
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bitterman Robert JPresident & CEOFeb 26 '24Buy0.912,5002,27518,990Feb 27 04:42 PM
Bitterman Robert JPresident & CEOJul 01 '23Buy2.841,0002,84019,211Jul 05 06:00 PM
Bitterman Robert JPresident & CEOJun 30 '23Buy2.881,0002,88018,211Jul 05 06:00 PM
Ferrara Robert LDirectorJun 14 '23Buy3.102,0006,2006,000Jun 15 05:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.